Fresenius SE & Co KGaA (FRE) PT Set at €66.00 by Independent Research

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €66.00 ($76.74) price target by equities researchers at Independent Research in a research report issued to clients and investors on Wednesday. The brokerage currently has a “neutral” rating on the stock. Independent Research’s target price would suggest a potential upside of 8.55% from the company’s current price.

A number of other brokerages have also recently issued reports on FRE. UBS Group set a €57.00 ($66.28) target price on shares of Fresenius SE & Co KGaA and gave the stock a “sell” rating in a research report on Monday, August 6th. DZ Bank reiterated a “buy” rating on shares of Fresenius SE & Co KGaA in a research report on Tuesday, August 7th. Deutsche Bank set a €82.00 ($95.35) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Thursday, July 19th. Warburg Research set a €80.00 ($93.02) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Thursday, October 4th. Finally, Sanford C. Bernstein set a €83.00 ($96.51) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Monday, July 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of €76.44 ($88.89).

Shares of Fresenius SE & Co KGaA stock opened at €60.80 ($70.70) on Wednesday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply